Evidence is strengthening for the morphological evaluation of tumor infiltrating lymphocytes
(TILs) in breast cancer. Herein, the concepts for TILs assessment are laid out by pathologists …

Background The objective of this systematic review and meta-analysis was to determine the
prognostic value of total tumor-infiltrating lymphocytes (TILs) and subtypes of TILs (CD4+ …

Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the
immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we …

CD8 T cell is an essential component of tumor-infiltrating lymphocytes (TIL) and tumor
immune microenvironment (TIME). Using the xCell CD8 T cell score of whole tumor gene …

Background In this study, we evaluated the ability of radiomic textural analysis of
intratumoral and peritumoral regions on pretreatment breast cancer dynamic contrast …

Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and
progesterone receptors and the absence of HER2 overexpression. These cancers represent …

Background: Not all breast cancer patients benefit from neoadjuvant or adjuvant therapy,
resulting in considerable undertreatment or overtreatment. New insights into the role of …

Expression of programmed cell death receptor ligand 1 (PDL1) has been scarcely studied in
breast cancer. Recently PD1/PDL1-inhibitors have shown promising results in different …

Around 40–50% of all triple-negative breast cancer (TNBC) patients achieve a pathological
complete response (pCR) after treatment with neoadjuvant chemotherapy (NAC). The …

Abstract Programmed death 1 ligand 1 (PD-L1) is an immune regulatory molecule that limits
antitumor immune activity. Targeting of PD-L1 and other immune checkpoint proteins has …